Search results for "Blood glucose"

showing 10 items of 437 documents

Longitudinal associations of physical activity and sedentary time with cardiometabolic risk factors in children

2018

BACKGROUND There are few prospective studies on the associations of changes in objectively measured vigorous physical activity (VPA∆ ), moderate-to-vigorous physical activity (MVPA∆ ), light physical activity (LPA∆ ), and sedentary time (ST∆ ) with changes in cardiometabolic risk factors (∆ ) in children. We therefore investigated these relationships among children. METHODS The participants were a population sample of 258 children aged 6-8 years followed for 2 years. We assessed PA and ST by a combined heart rate and movement sensor; computed continuous age- and sex-adjusted z-scores for waist circumference, blood pressure, and fasting insulin, glucose, triglycerides, and high-density lipop…

Blood GlucoseMaleCross-sectional studyphysical activityBlood Pressureliikunta030204 cardiovascular system & hematologyBody fat percentagechemistry.chemical_compound0302 clinical medicineHeart RateRisk FactorsInsulinOrthopedics and Sports MedicineLongitudinal StudiesProspective StudiesChildta315Prospective cohort studyFinlandAnthropometryriskitekijätLipidsCardiovascular DiseasesFemalelipids (amino acids peptides and proteins)Waist Circumferencefyysinen aktiivisuusmedicine.medical_specialtyWaistPhysical Therapy Sports Therapy and Rehabilitationpitkittäistutkimusta3111Article03 medical and health sciencesMetabolic DiseaseschildrenInternal medicineHeart ratemedicineHumansExerciselapsetCholesterolbusiness.industryterveydentila030229 sport sciencesAnthropometrycardiometabolic risk factorsCross-Sectional StudiesBlood pressurechemistrySedentary BehaviorbusinessScandinavian Journal of Medicine & Science in Sports
researchProduct

Physical Inactivity from Youth to Adulthood and Risk of Impaired Glucose Metabolism

2018

Introduction: Physical activity (PA) is important in the prevention and treatment of impaired glucose metabolism. However, association of physical inactivity during the transition between childhood and adulthood with glucose metabolism is unknown. Therefore, we studied the association of persistent physical inactivity since childhood with glucose metabolism in adulthood. Methods: Data were drawn from the ongoing, Cardiovascular Risk in Young Finns Study with repeated follow-ups between 1980 and 2011 (baseline age, 3-18 yr; n = 3596). Impaired glucose metabolism was defined as having impaired fasting glucose (6.1-6.9 mmol·L-1) or type 2 diabetes in adulthood. Leisure-time PA habits were repe…

Blood GlucoseMaleCross-sectional studyphysical activityType 2 diabetes030204 cardiovascular system & hematology0302 clinical medicineRisk FactorsSurveys and QuestionnairesOrthopedics and Sports MedicineLongitudinal Studies030212 general & internal medicineta315impaired glucose metabolismChildFinlandliikkumattomuusta3142Middle AgedaikuisuusChild PreschoolFemalefyysinen aktiivisuusAdultmedicine.medical_specialtyAdolescentPhysical Therapy Sports Therapy and RehabilitationpitkittäistutkimusCarbohydrate metabolism03 medical and health sciencesaineenvaihduntahäiriötInternal medicineDiabetes mellitusmedicineHumansExerciseLife Stylechildhoodbusiness.industryMetabolismlapsuusta3121medicine.diseaseImpaired fasting glucoseConfidence intervalCross-Sectional StudiesGlucoseEndocrinologyDiabetes Mellitus Type 2Relative riskphysical inactivitySedentary Behaviorbusinessaikuistyypin diabetesMedicine & Science in Sports & Exercise
researchProduct

Insulin resistance and endogenous digoxin-like factor in obese hypertensive patients with glucose intolerance

1992

Hypertensive obese subjects with glucose intolerance have hyperinsulinaemia, insulin resistance and intracellular cation imbalance resulting in increased sodium content. The aim of our study was to assess in these patients plasma levels of endogenous digoxin-like factor (EDLF), an inhibitor of the sodium-pump mechanism. We studied 14 hypertensive and 12 normotensive subjects with obesity and glucose intolerance for fasting blood glucose, and plasma insulin, C-peptide and EDLF levels: the two groups were matched for age and BMI and were studied after a 2-week wash-out period from hypotensive drugs. Compared with normotensives, hypertensive subjects had higher plasma insulin levels, a greater…

Blood GlucoseMaleDigoxinmedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentEndogenyEndogenous digoxin-like factorEndocrinologyInsulin resistanceInternal medicineDiabetes mellitusInternal MedicineHumansInsulinMedicineObesityImmunoreactive insulinC-Peptidebusiness.industryInsulinBlood ProteinsGeneral MedicineGlucose Tolerance TestMiddle AgedSaponinsmedicine.diseaseObesityCardenolidesEndocrinologyHyperglycemiaHypertensionFemaleInsulin ResistanceSodium-Potassium-Exchanging ATPasebusinessIntracellularActa Diabetologica
researchProduct

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-…

2017

Background: \ud Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes.\ud \ud Methods: \ud In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-…

Blood GlucoseMaleEXENATIDEType 2 diabetes030204 cardiovascular system & hematologyBody Mass Indexlaw.inventionPlacebosImpaired glucose toleranceMELLITUS3.0 MG0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawPREVENTION PROGRAM OUTCOMESPrediabetesPREVENTION PROGRAM OUTCOMES; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE; CLINICAL-TRIAL; OBESE SUBJECTS; 3.0 MG; REGRESSION; EXENATIDE; MELLITUSSubcutaneousMedicine (all)General MedicineMiddle AgedAdult; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus Type 2; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Obesity; Placebos; Prediabetic State; Risk Reduction Behavior; Treatment Outcome; Weight Loss3. Good healthTreatment OutcomeFemaleLIFE-STYLEType 2OBESE SUBJECTSmedicine.drugAdultmedicine.medical_specialtyInjections Subcutaneous030209 endocrinology & metabolismPlaceboIncretinsGlucagon-Like Peptide-1 ReceptorInjectionsCLINICAL-TRIALPrediabetic State03 medical and health sciencesIMPAIRED GLUCOSE-TOLERANCEDouble-Blind MethodDiabetes mellitusInternal medicineWeight LossREGRESSIONDiabetes MellitusmedicineHumansHypoglycemic AgentsObesityLiraglutidebusiness.industryBody WeightLiraglutidemedicine.diseaseClinical trialEndocrinologyDiabetes Mellitus Type 2Human medicinebusinessRisk Reduction Behavior[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe Lancet
researchProduct

Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1…

2012

OBJECTIVE We evaluated the addition of liraglutide to metformin in type 2 diabetes followed by intensification with basal insulin (detemir) if glycated hemoglobin (A1C) ≥7%. RESEARCH DESIGN AND METHODS In 988 participants from North America and Europe uncontrolled on metformin ± sulfonylurea, sulfonylurea was discontinued and liraglutide 1.8 mg/day added for 12 weeks (run-in). Subsequently, those with A1C ≥7% were randomized 1:1 to 26 weeks’ open-label addition of insulin detemir to metformin + liraglutide (n = 162) or continuation without insulin detemir (n = 161). Patients achieving A1C <7% continued unchanged treatment (observational arm). The primary end point was A1C change bet…

Blood GlucoseMaleEXENATIDEendocrine system diseasesdiabetes liraglutide metfortmin hypoglycemiaEndocrinology Diabetes and Metabolismmedicine.medical_treatmentType 2 diabetesTHERAPYGastroenterologyMELLITUSInsulin DetemirGlucagon-Like Peptide 1GLYCEMIC CONTROLOriginal ResearchInsulin detemirAged 80 and overClinical Care/Education/Nutrition/Psychosocial ResearchTREATED PATIENTSMiddle AgedMetforminMetforminNPH INSULINInsulin Long-ActingFemaleLife Sciences & Biomedicinehormones hormone substitutes and hormone antagonistsmedicine.drugAdultmedicine.medical_specialtyPARALLEL-GROUPAdolescentmedicine.drug_classHypoglycemiaEndocrinology & MetabolismDiabetes mellitusInternal medicineInternal MedicinemedicineHumansHypoglycemic AgentsCOMBINATIONAgedGlycated HemoglobinAdvanced and Specialized NursingScience & TechnologyLiraglutidebusiness.industryInsulin26-WEEKnutritional and metabolic diseasesLiraglutideEFFICACYmedicine.diseaseSulfonylureaEndocrinologyDiabetes Mellitus Type 2business
researchProduct

The impact of maternal weight in pregnancy on glucose metabolism in non-diabetic offspring in late adulthood

2019

Aims: We aimed to examine the association between maternal adiposity and glucose metabolism in adult offspring without diabetes, simultaneous taking offspring own adiposity into account. Methods: This longitudinal birth cohort study (Helsinki Birth Cohort Study) included 1,440 non-diabetic subjects examined at a mean age of 62 years. Subjects were divided into quartiles according to maternal body mass index (BMI). The impact of maternal BMI on offspring body composition was also studied. Results: There were no differences in fasting glucose between the groups. In men, maternal BMI was inversely associated with mean 2-hour glucose concentration after a 75 g oral glucose tolerance test (p <0.…

Blood GlucoseMaleEndocrinology Diabetes and MetabolismCHILDHOODPhysiologyraskausOverweightCohort Studies0302 clinical medicineEndocrinologyPregnancyMedicineMass indexLongitudinal StudiesMUSCLE MASS030212 general & internal medicineaineenvaihduntaRISK2. Zero hungerGlucose metabolismINSULIN-RESISTANCEylipainoGeneral MedicineInsulin sensitivityäiditGestational Weight Gainmaternal obesityOBESITYAdult ChildrenFemaleHEALTHmedicine.symptomAdultOffspringglucose metabolismOffspring health030209 endocrinology & metabolismBMI03 medical and health sciencesaineenvaihduntahäiriötInsulin resistanceMaternal obesityDiabetes mellitusInternal MedicineHumansinsulin sensitivitylapset (perheenjäsenet)offspring healthPregnancyOVERWEIGHTbusiness.industrynutritional and metabolic diseasesinsuliiniresistenssimedicine.diseaseBODY-MASS INDEXPANCREATIC BETA-CELL3121 General medicine internal medicine and other clinical medicineLean body masslihavuusGAINbusinessBody mass indexDiabetes Research and Clinical Practice
researchProduct

A 2 year physical activity and dietary intervention attenuates the increase in insulin resistance in a general population of children: the PANIC stud…

2020

Abstract Aims/hypothesis We studied for the first time the long-term effects of a combined physical activity and dietary intervention on insulin resistance and fasting plasma glucose in a general population of predominantly normal-weight children. Methods We carried out a 2 year non-randomised controlled trial in a population sample of 504 children aged 6–9 years at baseline. The children were allocated to a combined physical activity and dietary intervention group (306 children at baseline, 261 children at 2-year follow-up) or a control group (198 children, 177 children) without blinding. We measured fasting insulin and fasting glucose, calculated HOMA-IR, assessed physical activity and se…

Blood GlucoseMaleEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPhysiologyphysical activitylean body massruokavaliotBody fat percentageHOMA-IRlaw.inventionBody Mass Indexglukoosi0302 clinical medicineRandomized controlled triallawInsulinBody Size030212 general & internal medicineglucoseChildChildreninterventioneducation.field_of_studyBody movementinterventiotutkimusFastingSedentary timebody fatLean body massBody fatBody CompositionFemalefyysinen aktiivisuusinsulinPopulationsedentary time030209 endocrinology & metabolismlapset (ikäryhmät)InterventioninsuliiniArticle03 medical and health sciencesInsulin resistancechildrenHeart rateInternal MedicinemedicineHumanseducationExercisekehonkoostumusbusiness.industryPhysical activityInsulinmedicine.diseaseDietGlucoseLean body massInsulin Resistancebusinessdiet
researchProduct

Adrenic acid Δ4 desaturation and fatty acid composition in the liver of marine-oil fed streptozotocin diabetic rats

1998

The aim of the present study was to assess the effect of streptozotocin diabetes and insulin treatment on adrenic acid delta4 desaturation and fatty acid composition of liver microsomes in Wistar rats fed a fat free semi-synthetic basal diet supplemented with 10% EPA-rich marine oil. Results showed that, in liver microsomes of hyperglycemic rats, the 22:6n-3/22:5n-3 ratio in total lipids was elevated and desaturation of adrenic acid to n-6 docosapentaenoic acid was enhanced. Insulin treatment with 2.0 I.U./100 g body weight-1 twice a day for 3 days resulted in hypoglycemia and suppressed both the increased delta4 n-6 desaturation and 22:6n-3/22:5n-3 ratio. It is concluded that the delta4 de…

Blood GlucoseMaleErucic Acidsmedicine.medical_specialtymedicine.medical_treatmentClinical BiochemistryBiologyHypoglycemiaStreptozocinDiabetes Mellitus Experimentalchemistry.chemical_compoundFish OilsDiabetes mellitusInternal medicinemedicineAnimalsInsulinRats WistarChromatography High Pressure LiquidPancreatic hormoneInsulinFatty AcidsCell Biologymedicine.diseaseStreptozotocinLipidsEicosapentaenoic acidRatsEndocrinologyLiverBasal (medicine)chemistryFatty Acids UnsaturatedMicrosomes LiverDocosapentaenoic acidmedicine.drugProstaglandins, Leukotrienes and Essential Fatty Acids
researchProduct

Remodelling of biological parameters during human ageing: evidence for complex regulation in longevity and in type 2 diabetes.

2013

Factor structure analyses have revealed the presence of specific biological system markers in healthy humans and diseases. However, this type of approach in very old persons and in type 2 diabetes (T2DM) is lacking. A total sample of 2,137 Italians consisted of two groups: 1,604 healthy and 533 with T2DM. Age (years) was categorized as adults (≤65), old (66-85), oldest old (>85-98) and centenarians (≥99). Specific biomarkers of routine haematological and biochemical testing were tested across each age group. Exploratory factorial analysis (EFA) by principal component method with Varimax rotation was used to identify factors including related variables. Structural equation modelling (SEM) wa…

Blood GlucoseMaleGerontologyAgingAgeing Diabetes longevityPhysiologyType 2 diabetescentenarianHemoglobinsLeukocyte CountAged 80 and overPrincipal Component AnalysisHematologic TestsbiologyGeneral MedicineMiddle AgedExplained variationExploratory factor analysisexploratory factor analysiC-Reactive ProteinCholesteroldiabetic patientsItalyFemaleAnalysis of varianceAdultSTRUCTURAL EQUATION MODELINGAdolescentVarimax rotationLongevityAGEINGArticlemedicineHumansTriglyceridesAgedSettore MED/04 - Patologia GeneraleAnalysis of VarianceChi-Square DistributionC-reactive proteinFibrinogenmedicine.diseaseDiabetes Mellitus Type 2Ageingbiology.proteinGeriatrics and GerontologyFactor Analysis StatisticalChi-squared distributionBiomarkers
researchProduct

Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospe…

2019

Abstract Aims According to cardiovascular outcome trials, some sodium‐glucose contransporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are recommended for secondary cardiovascular prevention in type 2 diabetes (T2D). In this real‐world study, we compared the simultaneous reductions in HbA1c, body weight and systolic blood pressure after initiation of dapagliflozin or GLP‐1RA as second or a more advanced line of therapy. Materials and methods DARWIN‐T2D was a retrospective multi‐centre study conducted at diabetes specialist clinics in Italy that compared T2D patients who initiated dapagliflozin or GLP‐1RA (exenatide once weekly or liraglutide). Data were c…

Blood GlucoseMaleGlycated Hemoglobin AEndocrinology Diabetes and MetabolismBlood PressureType 2 diabetes030204 cardiovascular system & hematologySettore MED/13 - Endocrinologiachemistry.chemical_compound0302 clinical medicineEndocrinologyGlucosidesClinical endpointMedicineDapagliflozinGLP-1 analogueMiddle AgedTreatment Outcomeglycaemic controlantidiabetic drug; dapagliflozin; GLP-1 analogue; glycaemic control; observational studyCombinationOriginal ArticleDrug Therapy CombinationFemaleType 2medicine.drugAdultmedicine.medical_specialty030209 endocrinology & metabolismGlucagon-Like Peptide-1 Receptor03 medical and health sciencesDrug TherapyGLP-1 analogue; antidiabetic drug; dapagliflozin; glycaemic control; observational studyGLP‐1 analogueInternal medicineDiabetes mellitusInternal MedicineDiabetes MellitusHumansHypoglycemic AgentsBenzhydryl CompoundsAgedRetrospective StudiesGlycated Hemoglobinantidiabetic drugantidiabetic drug; dapagliflozin; GLP-1 analogue; glycaemic control; observational study; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus Type 2; Diabetic Angiopathies; Drug Therapy Combination; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Retrospective Studies; Treatment Outcomebusiness.industryLiraglutideBody WeightRetrospective cohort studyOriginal ArticlesdapagliflozinLiraglutidemedicine.diseaseBlood pressureDiabetes Mellitus Type 2chemistryPropensity score matchingExenatideobservational studybusinessAntidiabetic drug dapagliflozin GLP-1 analogue glycaemic control observational studyDiabetic Angiopathies
researchProduct